This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Oncology Podcasts

Conversations at ESMO 2025

Considering comorbidities in your mHSPC patients

ESMO 2025 Website Banner

At ESMO 2025, we had the privilege of sitting down with Dr. Mark Prentice to discuss a critical clinical question in the realm of metastatic hormone-sensitive prostate cancer (mHSPC): 

Which androgen receptor pathway inhibitor (ARPI) can effectively meet our treatment goals without compromising the patient’s quality of life?

Featuring:

In this engaging video, Dr Prentice tackles essential clinical topics, including 

  • NUBEQA (darolutamide) as a doublet treatment: 
    how does the availability of another ARPI option in this space address unmet needs?
  • Prioritising quality of life: 
    keeping quality of life at the heart of treatment decision making
  • Balancing comorbidities: 
    navigating cardiovascular conditions, patient frailty and potential drug-to-drug interactions in mHSPC patients

NUBEQA® (darolutamide) Prescribing Information

ESMO 2025
NUBEQA® (darolutamide)
PP-NUB-GB-2700, October 2025
Conversations at ESMO 2025
Doublet and triplet therapy in mHSPC – Who is the right patient?
PP-NUB-GB-2751, November 2025
NUBEQA® (darolutamide) Resources
PP-NUB-GB-2048, February 2025

PP-NUB-GB-2752 | November 2025